BBrussels Read More Meghan Markle and Prince Harry’s New Chapter: Can Brussels Change the Story?2026-11-07 For years, Meghan Markle and Prince Harry have remained two of the most discussed figures in modern royal…
BBrussels Read More Brussels suspects that the TikTok algorithm infringes the law and traps users in a bottomless pit2026-11-06 BrusselsNew push by the EU against TikTok. Brussels suspects that the platform’s algorithm infringes the Digital Services Act…
BBrussels Read More Can Brussels prohibit minors under 13 years old from accessing social networks?2026-09-17 Seven out of every ten minors use screens more than two hours a day, the recommended maximum Spanish…
NNovo Nordisk Read More Novo Nordisk’s Defining Moment: Can a Pill Outweigh a Pipeline Setback?2026-08-04 The arithmetic of Novo Nordisk’s share price has become uncomfortably simple. At Monday’s close of 40.83 euros, the…
NNovo Nordisk Read More Novo Nordisk’s Oral Wegovy Wins EU Nod: Can the Pill’s US Success Scale Across 27 Markets?2026-07-18 For millions of Europeans who have shunned weight-loss injections, the arrival of a daily pill could change the…
SStockholm Read More Congestion charging: What Auckland can learn from Stockholm2026-06-08 Stockholm’s congestion charging cut traffic 20% and queues by up to 50%. Photo / 123RF Auckland has a…
NNovo Nordisk Read More Novo Nordisk’s New Orleans Moment: Can CagriSema Data Reverse a 44% Slide?2026-06-01 Novo Nordisk’s 44% stock slide faces pivotal ADA test: Phase 3 CagriSema data for diabetes/obesity could restore confidence…
NNovo Nordisk Read More Novo Nordisk’s Pipeline Showdown: Can CagriSema and Zenagamtide Reverse the Stock’s Slide?2026-05-31 Novo Nordisk unveils CagriSema Phase 3 data at ADA after stock drop; oral Wegovy pill shows strong early…
NNovo Nordisk Read More Novo Nordisk’s Next Hurdle: August Earnings Will Test Whether Pill Uptake Can Counter a 65% Canadi2026-05-19 Novo Nordisk shares rebound 10% but remain down 15% YTD. Generic Ozempic competition looms in Canada, while oral…
NNovo Nordisk Read More Can a Pill and a Buyback Turn the Tide?2026-05-05 Novo Nordisk fights $400B value loss with a $2.2B buyback and oral Ozempic launch, but pricing pressure and…
VVestas Wind Systems Read More Can The Turbine Pioneer Regain Its Power On The Stock Market?2026-05-02 Vestas Wind Systems has been caught in the crosswinds of higher rates, policy delays and a vicious clean?tech…
ØØrsted Read More Can Offshore Wind’s Pioneer Win Back Investors?2026-04-27 Ørsted’s stock has been on a roller coaster as offshore wind faces a brutal reset in costs, contracts,…